Allarity Therapeutics partners with Indiana Biosciences Research Institute to study stenoparib's dual mechanism

Allarity Therapeutics, Inc.

Collaboration aims to clarify contributions of PARP inhibition and WNT pathway modulation to stenoparib's anticancer effects.
Stenoparib is a dual PARP1/2 and tankyrase1/2 inhibitor currently in Phase 2 trial for advanced ovarian cancer.
Research may support future marketing approval and potential expansion into colorectal cancer and SCLC combination trial.
No financial terms of the collaboration were disclosed in the press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.